Callisto Pharmaceuticals Inc. 

03.01.2013 22:31
---------------------------------------------------------------------------

NEW YORK, 2013-01-03 22:31 CET (GLOBE NEWSWIRE) --
Callisto Pharmaceuticals, Inc. (OTCBB:CLSP) ('Callisto') today announced that
it convened its special meeting of stockholders on Thursday, January 3, 2013
and adjourned the meeting until Monday, January 14, 2013, at 1:00 p.m., Eastern
Standard Time. The special meeting was adjourned to allow the company's
stockholders a reasonable amount of time to consider the recent announcement,
by Synergy Pharmaceuticals Inc., of the results of its Phase IIb/III clinical
trial. 

The reconvened special meeting will be held at Callisto's offices, 420
Lexington Avenue, Suite 1609, New York, NY 10170. Stockholders who have already
voted do not need to recast their votes. Proxies previously submitted in
respect of the meeting will be voted at the adjourned meeting unless properly
revoked. Given the adjournment, proxies may now be received by our registrar
and transfer agent, Philadelphia Stock Transfer Inc., no later than January 13,
2013 at 11:59 p.m. (Eastern Standard Time). 

About Callisto Pharmaceuticals Inc.

Callisto is a development stage biopharmaceutical company. All of Callisto's
drug candidates, currently plecanatide and SP-333 to treat GI disorders and
diseases, are being developed exclusively by Synergy Pharmaceutical Inc. 


         CONTACT: Investor Contact:
         Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924
News Source: NASDAQ OMX



03.01.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Callisto Pharmaceuticals Inc.
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------